Last $0.65 USD
Change Today -0.10 / -13.33%
Volume 1.0K
MTST On Other Exchanges
As of 8:10 PM 08/22/14 All times are local (Market data is delayed by at least 15 minutes).

metastat inc (MTST) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/24/14 - $1.92
52 Week Low
08/19/14 - $0.56
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for METASTAT INC (MTST)

Related News

No related news articles were found.

metastat inc (MTST) Related Businessweek News

No Related Businessweek News Found

metastat inc (MTST) Details

MetaStat, Inc., a life sciences company, focuses on developing and commercializing novel diagnostic technologies and therapeutics for prediction and treatment of systemic metastasis. Its MetaSite Breast and MenaCalc diagnostic product lines are designed to predict the probability of cancer metastasizing. These are intended to allow clinicians to customize cancer treatment decisions by identifying and differentiating high-risk patients who need aggressive therapy and by sparing low-risk patients from the harmful side effects and expense of chemotherapy and radiation therapies. The company’s MenaCalc diagnostic platform is also applicable in solid epithelial-based cancers, including breast, prostate, lung, and colorectal. In addition, it is developing therapeutic programs that understand the mena biology and alternative splicing events as drivers of disease progression, which allows identifying novel targets and develop new classes of chemotherapy. Metastat, Inc. is based in Montclair, New Jersey.

6 Employees
Last Reported Date: 06/13/14

metastat inc (MTST) Top Compensated Officers

Chief Executive Officer, Chief Medical Office...
Total Annual Compensation: $194.2K
Founder, President, Chief Financial Officer, ...
Total Annual Compensation: $175.0K
Vice President of Finance and Controller
Total Annual Compensation: $137.0K
Compensation as of Fiscal Year 2014.

metastat inc (MTST) Key Developments

MetaStat, Inc. announced delayed annual 10-K filing

On 05/28/2014, MetaStat, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

MetaStat, Inc. Replaces MaloneBailey, LLP with EisnerAmper LLP as Principal Accountant

On March 7, 2014, MetaStat, Inc. engaged EisnerAmper LLP as its principal accountant and dismissed MaloneBailey, LLP from that role. The change in accountants was approved by the company's Audit Committee and did not result from any dissatisfaction with the quality of professional services rendered by MaloneBailey.

MetaStat, Inc. Presents at 26th Annual ROTH Conference, Mar-12-2014 12:30 PM

MetaStat, Inc. Presents at 26th Annual ROTH Conference, Mar-12-2014 12:30 PM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States. Speakers: Oscar M. Bronsther, Chief Executive Officer, Chief Medical Officer and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MTST:US $0.65 USD -0.10

MTST Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MTST.
View Industry Companies

Industry Analysis


Industry Average

Valuation MTST Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact METASTAT INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at